India Pharma Outlook Team | Wednesday, 14 October 2026
Indian pharma innovation is emerging as a strategic priority as the country looks beyond its established strength in generic medicines and aims towards higher-value drug development.
Biocon and Syngene International Executive Chairperson Kiran Mazumdar-Shaw recently called for sustained investment in research, faster regulatory approvals and stronger collaboration between pharmaceutical companies and regulators.
Speaking virtually at the IFQM Symposium 2026, she pointed out India's potential to turn laboratory discoveries into marketable drugs.
However, achieving this transition will require more than just expertise in manufacturing.
Companies must strengthen research pipelines, expand clinical development capabilities and ensure sustained investments in medicines which may take years to reach consumers.
India's established generics industry provides an important foundation, but higher-value drug development programs generally involve greater scientific and financial uncertainty.
Companies must identify promising drug candidates, conduct preclinical studies, complete clinical trials and secure regulatory approval before commercialization.
Mazumdar also emphasized that India cannot allow its drug development pipeline to stagnate and encouraged India to benchmark itself against China as it aims to strengthen its position in global pharma innovation.
Company disclosures illustrate the investment already taking place:
Also Read: Sterile Injectable CDMO in India: Manufacturing, Fill-Finish, Technology & Regulatory Guide 2026
A promising molecule needs solid clinical evidence before it can become an approved drug.
For Indian pharma innovation to move forward, the country requires qualified investigators, well-equipped hospitals, trained research teams and a dependable trial management system.
The government announced Biopharma SHAKTI, with an outlay of Rs 10,000 crore over five years, in the Union Budget 2026–27.
Its proposed components include a network of 1,000 accredited clinical trial sites, stronger biopharma research institutions and additional scientific expertise at the Central Drugs Standard Control Organization.
Existing initiatives also provide a foundation:
While funding and infrastructure lay the groundwork, companies must also be prepared to handle the risk of clinical failures, extended development cycles and uncertain regulatory timelines.
Mazumdar called on developers to harness AI and digital technologies to streamline the review process and stressed the need for regulatory reform and closer collaboration.
The next phase of Indian pharma innovation will depend on whether companies can translate research investment into viable drug candidates, credible clinical evidence and successful launches.
Maintaining the strengths of the generics industry while building capabilities in complex medicines and novel therapies could help India move towards a more innovation-led pharmaceutical model.
.jpg)
